Indian mental health app Lissun raises $3M for AI advancements

Indian mental health platform Lissun has successfully raised $2.5 million in a pre-Series A funding round, with RPSG Capital Ventures leading the investment. The new infusion of capital is set to help Lissun integrate artificial intelligence into its array of digital mental health solutions. This expansion aims to cater specifically to corporates, educational institutions, and families with children experiencing neurodevelopmental conditions. Additionally, the funds will be used to broaden their service offerings and to expand their team. The latest investment brings Lissun's total funding to $5 million, following over $1 million in seed funding secured in September of the previous year.

Asan Medical Center (AMC) in South Korea has made strides in the field of digital therapeutics by becoming the first to prescribe a locally-approved treatment for vision impairment due to stroke. The digital therapeutic, known as Vivid Brain, is a mobile application that utilizes virtual reality to improve a user's responsiveness to visual stimuli. Officially prescribed by AMC in September, five months after receiving clearance from the Korean government, Vivid Brain is the third locally-approved digital therapeutic in the country. Developed by AMC professor Kang Dong-hwa in collaboration with Nunaps, a local company he founded, there are plans to expand the availability of this digital therapeutic to hospitals both within South Korea and internationally.

In another significant development in the medical field, Korean AI medical imaging company Neurophet has entered into a new partnership aimed at enhancing the diagnosis of Alzheimer's disease. Neurophet will be collaborating with Aribio, a local biotechnology company specializing in treatments for neurodegenerative diseases. The partnership intends to combine Neurophet's MRI-based image analysis software with Aribio's blood-based diagnostic test for detecting Alzheimer's. This integrated approach aims to identify individuals with Alzheimer's-related amyloid beta protein deposits in their brains. According to the company, this solution is designed to make Alzheimer's testing more accessible and to reduce the need for repetitive and costly amyloid-PET imaging tests. The collaboration builds on the existing global clinical trial work for Aribio's oral Alzheimer's treatment AR1001, which is currently in phase three. In July, Neurophet also introduced the Neurophet AQUA AD, their latest software for Alzheimer's treatment prescription and monitoring.